Applied Materials Sinks 17% in a Week After a Forecast-Free Investor Day: “Tremendous Confidence” ©@Kittipong Jirasukhanont from PhonlamaiPhoto’s Images via Canva, @Iulian Catalin’s Images via Canva Key Takeaways Applied Materials stock has declined 24% since October 12, including a 6.7% drop following its October 13 investor presentation. Management outlined ambitious 2030 profitability targets but declined

The S&P 500 (SNPINDEX:^GSPC) and Nasdaq Composite (NASDAQINDEX:^IXIC) have added 12% in 2026 despite a number of economic headwinds. That puts both indexes on pace for their fourth consecutive year of double-digit gains for the first time since the late 1990s. However, investors recently got bad news about the economy. Inflation accelerated in September, as

Palantir (NASDAQ: PLTR) investors have had a fairly rocky 2026. For most of the year, the stock was losing money. However, starting in August, Palantir reversed the decline and has now gained about 12% for the year. That is roughly in line with the gain for the S&P 500 (SNPINDEX: ^GSPC). However, if you survey

3 Reasons to sell NEOG and 1 stock to buy instead Neogen’s 25.9% return over the past six months has outpaced the S&P 500 by 16.8%, and its stock price has climbed to $11.78 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Oil just hit a five month high as supply risks from the Middle East and attacks on key energy facilities push energy markets back into the spotlight. When crude prices get this much attention, the largest integrated producers and pipeline giants can draw fresh investor interest. This article walks through three leading global oil and

The AI trade has looked awfully shaky over the last couple of weeks. CoreWeave, the neocloud company that may have more leveraged exposure to AI than any other company due to its massive debt burden, has plunged in recent weeks on fears over its rising debt yields. Missed AI’s “Act 1”? Act 2 Could Be

Hormel Foods has seen its share price slide over the past few years, and that drop puts a spotlight on a simple question for investors who focus on fundamentals. Is the current valuation of Hormel stock still in line with the earnings power the business is producing today? Over the past 5 years, the share

Biotech stocks live and die on access to capital, so the Federal Reserve’s signal that interest rates may pause for now gives this high risk corner of the market some breathing room. Cheaper money can make it easier to fund drug pipelines and clinical trials, which matters if you are hunting for the next breakthrough.